AmpC Beta-Lactamase Detection: Cefoxitin Screen, Inhibitor Confirmation, and Telling It Apart from an ESBL

AmpC beta-lactamases are one of the most commonly missed resistance mechanisms in routine susceptibility testing. An AmpC-producing bacterium may appear susceptible to a third-generation cephalosporin in the laboratory, but the same antibiotic can fail during treatment because AmpC production is inducible and may become fully expressed (derepressed) after antibiotic exposure.

Unlike ESBLs, AmpC enzymes are not inhibited by clavulanic acid. As a result, the standard ESBL confirmatory test does not detect AmpC. Even more importantly, when AmpC and ESBL are produced together, AmpC can mask the ESBL and cause the test to appear falsely negative.

Detecting AmpC is based on one key principle: what inhibits it and what does not. It is inhibited by boronic acid and cloxacillin, but not by clavulanic acid. This simple difference distinguishes AmpC from ESBL, forms the basis of all confirmatory tests, and is the source of much of the confusion.

What an AmpC enzyme is, and why it evades routine testing

AmpC beta-lactamases are Ambler Class C, Bush-Jacoby Group 1 cephalosporinases. (The Ambler and Bush-Jacoby classification systems are explained in full in the beta-lactamase classification article). They hydrolyze penicillins, cephamycins (such as cefoxitin), and first-, second-, and third-generation cephalosporins, and they resist beta-lactam/beta-lactamase-inhibitor combinations. They remain susceptible to cefepime and to carbapenems.

Two features make AmpC a detection problem. First, many AmpC enzymes are inducible: baseline production is low, so the isolate can look susceptible, but exposure to a beta-lactam ramps up enzyme production and unmasks resistance during therapy. Second, AmpC is not inhibited by clavulanic acid, so it slips straight past the ESBL confirmatory test that relies on clavulanate synergy.

Chromosomal vs. plasmid-mediated AmpC

Knowing which type you are dealing with changes the interpretation.

Chromosomal AmpC is native to certain organisms, classically the group remembered by the mnemonic below (Enterobacter, Citrobacter, Serratia, and others). In these, AmpC is expected and typically inducible; the question is not "is AmpC present" but "will it express on treatment."

Plasmid-mediated AmpC (pAmpC) is acquired, and it appears in organisms that do not normally carry a chromosomal ampC, principally Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, and Salmonella. Because these species have no native AmpC, finding AmpC activity in them signals a transferable, plasmid-borne enzyme. Most phenotypic detection tests are validated specifically for pAmpC in these AmpC-lacking species.

Step 1: Screening with cefoxitin

The first step in detecting AmpC is to test susceptibility to cefoxitin, a cephamycin antibiotic. ESBL-producing bacteria usually remain susceptible to cefoxitin, whereas AmpC-producing bacteria can hydrolyze cefoxitin and become resistant. Therefore, cefoxitin resistance is an early sign of possible AmpC production.

Note that, unlike ESBL detection, there are no CLSI-approved interpretive criteria for AmpC. The cutoffs below are widely used, well-validated research and consensus criteria rather than formally standardized breakpoints.

In the disk diffusion method, a cefoxitin (30 µg) zone diameter of less than 18 mm is considered a positive screening result and indicates that confirmatory testing should be performed. However, a positive screening test does not confirm AmpC. Other mechanisms, such as reduced porin permeability, can also decrease the cefoxitin zone size even when AmpC is not present. This is why a confirmatory test is always required.

Step 2: Confirmation with an AmpC inhibitor

Confirmation uses the defining property: AmpC is inhibited by boronic acid and by cloxacillin. Adding one of these should restore cefoxitin activity if AmpC is the cause.

Cefoxitin-cloxacillin double-disk test. Cloxacillin inhibits AmpC. A cefoxitin-cloxacillin disk is compared against a plain cefoxitin disk. A zone diameter ≥4 mm larger with cloxacillin than without confirms AmpC production. This is simple, cheap, and widely used in resource-limited labs.

Boronic acid disk test. Boronic acid (phenylboronic acid) is a reversible AmpC inhibitor. Cefoxitin (or cefotetan) is tested alone and with boronic acid added; a ≥5 mm increase in zone diameter with boronic acid confirms AmpC. Boronic acid also inhibits KPC carbapenemases, so this reagent reappears in carbapenemase work, a useful thing to remember rather than relearn.

AmpC disk test (Tris-EDTA). A cefoxitin-susceptible E. coli ATCC 25922 lawn is plated. A disk impregnated with Tris-EDTA (which permeabilizes the test organism and releases its beta-lactamases) plus the test organism is placed at the edge of the cefoxitin zone. A flattening or indentation of the E. coli inhibition zone next to the disk indicates AmpC. This is sensitive and specific but needs the EDTA-disk reagent.

Step 3: Telling AmpC apart from ESBL

This is where AmpC and ESBL detection meet, and it is the highest-yield concept to master. Two enzymes, two inhibitors, and the pattern of which inhibitor works tells you which enzyme you have.

The clean logic: clavulanate synergy means ESBL; boronic-acid or cloxacillin synergy means AmpC. When an isolate is resistant to cefoxitin and fails the ESBL confirmatory test, suspect AmpC. When an isolate co-produces both, the AmpC masks the ESBL (clavulanate cannot restore the cephalosporin because the AmpC keeps destroying it), and the ESBL only becomes visible once the AmpC is neutralized, either on cloxacillin-containing media or by adding boronic acid to the ESBL test. This masking effect is a common reason a true ESBL is missed.

Why it matters at the bedside

An unrecognized AmpC producer treated with a third-generation cephalosporin risks clinical failure, because the enzyme derepresses under selective pressure even when the initial report reads susceptible. The safe therapeutic choices against a confirmed AmpC producer are cefepime (a weak AmpC inducer and poor substrate) or a carbapenem. Detection also matters for infection control: a plasmid-mediated AmpC in E. coli or Klebsiella is transferable and warrants the same containment attention as any mobile resistance determinant. Detection feeds the antibiogram and antimicrobial stewardship decisions for the next patient.

How to Remember

The whole idea in one contrast: two enzymes hide behind cephalosporin resistance, and the inhibitor that unmasks them tells them apart. Clavulanate opens the door on an ESBL. Boronic acid or cloxacillin opens the door on an AmpC. If cefoxitin is resistant, the door with the AmpC behind it is the one to try.

Which bugs carry chromosomal AmpC (classic mnemonic): remember the classic chromosomal-AmpC organisms as a group: Enterobacter, Citrobacter (freundii), Serratia, Morganella, Providencia, and Hafnia. A common mnemonic is "CHESPM," but the plainer point is that these species carry AmpC on the chromosome, so it is expected in them, and (for the acquired plasmid version) the AmpC-lacking hosts E. coli, Klebsiella, Proteus, Salmonella. The teaching point is the split: if AmpC turns up in the second group, it came in on a plasmid.

The inducibility image: an inducible AmpC is a dimmer switch, not an on/off switch. On the plate under low light it looks susceptible. Give it a beta-lactam and it brightens (derepresses), which is why a susceptible report can still fail the patient.

Key exam facts in one table

Where Students Get Confused

"AmpC and ESBL are detected the same way." No, and this is the crux. ESBL is confirmed by clavulanate synergy; AmpC is confirmed by boronic-acid or cloxacillin synergy. Clavulanate does nothing to AmpC. Using the ESBL test alone will miss every AmpC.

"A susceptible cephalosporin result rules out AmpC." No. Inducible AmpC can read susceptible at baseline and derepress under therapy, causing failure. This is why detection, not just the routine MIC, matters for these organisms.

"Cefoxitin resistance proves AmpC." No, it screens for it. Porin loss can also reduce the cefoxitin zone. A positive screen must go to a confirmatory inhibitor test.

"If the ESBL test is negative, there is no ESBL." Not when AmpC is present. A co-produced AmpC masks the ESBL by continuing to hydrolyze the cephalosporin despite clavulanate. Neutralize the AmpC (cloxacillin media or added boronic acid) and the hidden ESBL appears.

"Boronic acid is only an AmpC reagent." It also inhibits KPC carbapenemases, which is why it reappears in carbapenemase detection. Same reagent, different context.

References

1. Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. M100, current edition. Wayne, PA: CLSI.
2. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161-182. doi:10.1128/CMR.00036-08
3. Black JA, Moland ES, Thomson KS. AmpC disk test for detection of plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae lacking chromosomal AmpC beta-lactamases. J Clin Microbiol. 2005;43(7):3110-3113. doi:10.1128/JCM.43.7.3110-3113.2005
4. Coudron PE. Inhibitor-based methods for detection of plasmid-mediated AmpC beta-lactamases in Klebsiella spp., Escherichia coli, and Proteus mirabilis. J Clin Microbiol. 2005;43(8):4163-4167. doi:10.1128/JCM.43.8.4163-4167.2005
5. Tille PM. Bailey & Scott's Diagnostic Microbiology. 15th ed. St. Louis: Elsevier; 2022.